How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

5,222 results for

adhd exercise

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

5181. Implementing the American Academy of Pediatrics attention-deficit/hyperactivity disorder diagnostic guidelines in primary care settings. Full Text available with Trip Pro

Implementing the American Academy of Pediatrics attention-deficit/hyperactivity disorder diagnostic guidelines in primary care settings. To evaluate the feasibility of the San Diego Attention-Deficit/Hyperactivity Disorder Project (SANDAP) protocol, a pediatric community-initiated quality improvement effort to foster implementation of the American Academy of Pediatrics (AAP) attention-deficit/hyperactivity disorder (ADHD) diagnostic guidelines, and to identify any additional barriers (...) , including quantitative surveys with parents and teachers and qualitative debriefing sessions conducted an average of 3 times per year with pediatricians and office staff members.Between December 2000 and April 2003, 159 children were consecutively enrolled for evaluation of school and/or behavioral problems. Clinically, only 44% of the children met criteria for ADHD on both the parent and teacher scales, and 73.5% of those children were categorized as having the combined subtype. More than 40

2004 Pediatrics

5182. Self-regulation of slow cortical potentials: a new treatment for children with attention-deficit/hyperactivity disorder. Full Text available with Trip Pro

their excitation threshold. This training aims at regulation of cortical excitation thresholds considered to be impaired in children with attention-deficit/hyperactivity disorder. Electroencephalographic data from the training and the 6-month follow-up are reported, as are changes in behavior and cognition.Twenty-three children with attention-deficit/hyperactivity disorder aged between 8 and 13 years received 30 sessions of self-regulation training of slow cortical potentials in 3 phases of 10 sessions each (...) are reported. Measurement before and after the trials showed that children with attention-deficit/hyperactivity disorder learn to regulate negative slow cortical potentials. After training, significant improvement in behavior, attention, and IQ score was observed. The behavior ratings included Diagnostic and Statistical Manual of Mental Disorders criteria, number of problems, and social behavior at school and were conducted by parents and teachers. The cognitive variables were assessed with the Wechsler

2006 Pediatrics

5183. Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. Full Text available with Trip Pro

Worse quality of life for children with newly diagnosed attention-deficit/hyperactivity disorder, compared with asthmatic and healthy children. To evaluate the quality of life (QOL) of untreated children with newly diagnosed attention-deficit/hyperactivity disorder (ADHD), compared with asthmatic and healthy children.This prospective, case-control study included a group of 120 children, 6 to 12 years of age, with newly diagnosed ADHD according to the Diagnostic and Statistical Manual of Mental (...) Disorders, Fourth Edition. Subjects were matched according to age, gender, and health care area with 2 control groups, ie, 93 asthmatic children and 120 healthy children. Sociodemographic characteristics and Child Health Questionnaire scores were collected.The QOL of children with ADHD was rated worse than that of asthmatic or healthy children for most Child Health Questionnaire domains. The greatest differences were found in behavior, social limitations attributable to physical problems, emotional

2005 Pediatrics

5184. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. Full Text available with Trip Pro

Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder. The aim of treatment for attention-deficit/hyperactivity disorder (ADHD) is to decrease symptoms, enhance functionality, and improve well-being for the child and his or her close contacts. However, the measurement of treatment response is often limited to measuring symptoms using behavior rating scales and checklists completed by teachers and parents. Because so much (...) (BE), emotional impact on parent (PTE), and time impact on parents (PTT). A separate domain measures limitations in family activities (FA). There is also a single-item measure of family cohesion (FC). Individual scale scores and summary scores for physical (PhS) and psychosocial health (PsS) can be computed. Symptom severity data (parent and teacher) came from the Child/Adolescent Symptom Inventory 4. These checklists provide information on symptoms for the 3 ADHD subtypes (inattentive, hyperactive

2004 Pediatrics

5185. Does connection to primary care matter for children with attention-deficit/hyperactivity disorder? (Abstract)

Does connection to primary care matter for children with attention-deficit/hyperactivity disorder? Whether high-quality primary care in the form of a medical home effectively meets the health care needs of children with attention-deficit/hyperactivity disorder is unknown. The objectives of this study were to (1) describe the percentage who report unmet health care need, (2) evaluate whether having a medical home is associated with lower risk for having unmet needs, and (3) compare the impact (...) of having a medical home on unmet need for children with attention-deficit/hyperactivity disorder with those with asthma.Cross-sectional analysis was conducted of the National Survey of Children's Health, 2003, a nationally representative sample. The primary outcome variable was parent-reported unmet health care need. Multivariate logistic regression tested the impact of having a medical home on unmet needs for children with attention-deficit/hyperactivity disorder and asthma.The National Survey

2008 Pediatrics

5186. Unexpected effects of methylphenidate in attention-deficit/hyperactivity disorder reflect decreases in core/secondary symptoms and physical complaints common to all children. Full Text available with Trip Pro

children in the general population. Sixty-five children with attention-deficit/hyperactivity disorder (ADHD) participated in a double-blind, placebo-controlled, within-subject (crossover) experimental design and received a placebo and four MPH doses in counterbalanced order following baseline assessment. Behavioral and physical complaints were significantly higher under baseline relative to placebo and the four immediate-release MPH conditions (5 mg, 10 mg, 15 mg, and 20 mg) across three symptom (...) Unexpected effects of methylphenidate in attention-deficit/hyperactivity disorder reflect decreases in core/secondary symptoms and physical complaints common to all children. Abstract Hypotheses concerning unexpected, psychostimulant-related effects reported in previous studies were examined by separating behavioral/physical complaints highly specific to methylphenidate (MPH) from those that (a) may mimic core/secondary symptoms of the disorder, or (b) are commonly reported by unmedicated

2008 Journal of Child and Adolescent Psychopharmacology

5187. Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicent (Abstract)

-deficit/hyperactivity disorder (ADHD).The goal of this study was to assess the efficacy and safety of mixed amphetamine salts extended release (MAS XR) for the treatment of ODD in children and adolescents aged 6 to 17 years.This was a 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study. Patients were randomized to receive active treatment with MAS XR 10, 20, 30, or 40 mg/d or placebo. The primary efficacy end point was the ODD subscale (...) Efficacy and safety of mixed amphetamine salts extended release (adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit/hyperactivity disorder in school-aged children and adolescents: A 4-week, multicent Oppositional defiant disorder (ODD)is associated with a high degree of impairment in social skills, family interaction, and academic functioning. Comorbid ODD is reportedly present in 40% to 70% of children and adolescents with attention

2006 Clinical therapeutics Controlled trial quality: predicted high

5188. Attention Deficit Hyperactivity Disorder

and based on research evidence, UK and European Guidelines. You may find the article more useful, or one of our other . In this article In This Article Attention Deficit Hyperactivity Disorder In this article Synonyms: hyperkinetic disorder, attention deficit disorder (ADD) Attention deficit hyperactivity disorder (ADHD) is a persistent pattern of inattention and/or hyperactivity and impulsivity that is more frequent and severe than is typically observed in individuals at a comparable level (...) Attention Deficit Hyperactivity Disorder ADD or Attention Defecit and Hyperactivity Disorder - Patient | Patient TOPICS Try our Symptom Checker TREATMENT RESOURCES Try our Symptom Checker PROFESSIONAL Upgrade to Patient Pro / / Search Attention Deficit Hyperactivity Disorder Authored by , Reviewed by | Last edited 16 Apr 2014 | Certified by This article is for Medical Professionals Professional Reference articles are designed for health professionals to use. They are written by UK doctors

2008 Mentor

5189. Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD)

-Deficit/Hyperactivity Disorder (ADHD). Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder Drug: Atomoxetine Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 45 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: An Open Study of Atomoxetine (LY139603) in Adult Subjects With Attention-deficit/Hyperactivity (...) Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD) Atomoxetine Asian Study in Adult Subjects With Attention-Deficit/Hyperactivity Disorder (ADHD) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2008 Clinical Trials

5190. Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

chronically under regular clinical conditions either as monotherapy or in combination with stimulant therapy to children and adolescents with attention deficit hyperactivity disorder (ADHD). Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder Drug: CLONICEL (Clonidine HCl sustained release) Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 303 participants Intervention Model: Single Group (...) terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Clonidine Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Antihypertensive Agents Sympatholytics Autonomic Agents Adrenergic alpha-2 Receptor Agonists Adrenergic alpha-Agonists

2008 Clinical Trials

5191. Pharmacogenetic Study of Methylphenidate in Attention Deficit/Hyperactivity Disorder(ADHD)

, 2008 Last Update Posted: October 5, 2011 Last Verified: December 2010 Keywords provided by Hallym University Medical Center: ADHD, norepinephrine transporter pharmacogenetics Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Methylphenidate Norepinephrine (...) and adverse effects of OROS-methylphenidate in treatment of ADHD. Condition or disease Intervention/treatment Phase Attention Deficit Disorder With Hyperactivity Methylphenidate Pharmacogenetics Genetic: norepinephrine transporter polymorphism, Phase 4 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 150 participants Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose

2008 Clinical Trials

5192. Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children

: September 17, 2008 Results First Posted: February 21, 2018 Last Update Posted: February 21, 2018 Last Verified: February 2018 Keywords provided by Joan Daughton, MD, University of Nebraska: Attention Deficit Hyperactivity Disorder Stimulant Treatment Young Children Additional relevant MeSH terms: Layout table for MeSH terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic (...) Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children Long Acting Stimulant Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Young Children - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please

2008 Clinical Trials

5193. Pharmacokinetics of Two Extended-Release Formulations of Methylphenidate in Children With Attention Deficit Hyperactivity Disorder (ADHD)

, 2009 Last Verified: January 2009 Keywords provided by University Hospital Freiburg: ADHD Attention Deficit Disorder Attention Deficit an Disruptive Behavior Disorders Children Central Nervous System Stimulants Methylphenidate Pharmacokinetics Area Under Curve Therapeutic Equivalency Psychopharmacology Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders (...) objective of the study is to determine the pharmacokinetic parameters and bioequivalence of Ritalin LA compared to Medikinet retard, both given as oral o.d. doses of 20 mg over 7 days in children with ADHD. The secondary objectives are to assess the efficacy, safety and tolerability of Ritalin LA and Medikinet retard and the association of these parameters with plasma levels. Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder Drug: Methylphenidate Phase 1 Phase 2

2008 Clinical Trials

5194. New Continuous Performance Tests (CPT) for the Diagnosis of Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

2009 Keywords provided by Hadassah Medical Organization: CPT ADHD Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms (...) child difficulties and covers a wider range of needs. So, it can be helpful to a larger variety of children with different needs. Condition or disease Attention Deficit Hyperactivity Disorder Detailed Description: Computerized continuous performance tests (CPT) considered the "gold standard" for diagnosis of Attention Deficit/Hyperactivity Disorder (ADHD) and are widely used. This type of tests measures the number of correctly detected stimuli as well as response time. The diagnosis in this tests

2008 Clinical Trials

5195. Dose Finding Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)(174007/P05805/MK-8777-003)

-week treatment periods will be separated by a 2-week placebo washout period. The primary objective is to compare the efficacy of various doses of MK-8777 to that of placebo in the treatment of ADHD symptoms in adults. Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder Drug: MK-8777 Drug: Placebo Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 67 participants Allocation: Randomized (...) Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms

2008 Clinical Trials

5196. Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

Identifier: NCT00556959 Recruitment Status : Completed First Posted : November 12, 2007 Last Update Posted : March 24, 2010 Sponsor: Addrenex Pharmaceuticals, Inc. Information provided by: Addrenex Pharmaceuticals, Inc. Study Details Study Description Go to Brief Summary: The purpose of this study is to determine whether CLONICEL® (clonidine HCl sustained release) is a safe and effective treatment for children and adolescents with attention deficit hyperactivity disorder (ADHD). Condition or disease (...) Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Clonidine Analgesics Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Antihypertensive Agents Sympatholytics Autonomic Agents Adrenergic alpha-2

2007 Clinical Trials

5197. Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE

Disorder) symptoms in adolescents with ADHD and comorbid cannabis abuse. Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder Cannabis Abuse Drug: Atomoxetine Phase 4 Detailed Description: In the past adolescents with cannabis abuse have been excluded from studies in which atomoxetine for ADHD symptoms was studied. In this study the efficacy of atomoxetine on symptoms of ADHD in adolescents with ADHD and comorbid cannabis abuse will be studied. Study Design Go (...) 19, 2010 Last Update Posted: August 24, 2010 Last Verified: August 2010 Keywords provided by Eli Lilly and Company: Attention Deficit Hyperactivity Disorder with Cannabis Abuse Marihuana Abuse Comorbid Cannabis Abuse Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Marijuana Abuse Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic

2008 Clinical Trials

5198. Safety and Tolerability Study of ABT-089 in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)

: January 18, 2013 Sponsor: AbbVie (prior sponsor, Abbott) Information provided by (Responsible Party): AbbVie ( AbbVie (prior sponsor, Abbott) ) Study Details Study Description Go to Brief Summary: The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for children with Attention Deficit Hyperactivity Disorder (ADHD). Condition or disease Intervention/treatment Phase Attention-Deficit/Hyperactivity Disorder Drug: ABT-089 Drug: placebo Phase 2 (...) table for eligibility information Ages Eligible for Study: 6 Years to 12 Years (Child) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Have voluntarily signed an informed consent form. Meet diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD) based on detailed evaluation and interview with parent(s). Subject is generally in good health based on medical history, physical examination, clinical lab tests and ECG. Subject weights at least 37

2008 Clinical Trials

5199. Safety, Tolerability and Efficacy Study of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Last Update Posted : January 18, 2013 Sponsor: AbbVie (prior sponsor, Abbott) Information provided by (Responsible Party): AbbVie ( AbbVie (prior sponsor, Abbott) ) Study Details Study Description Go to Brief Summary: The purpose of this study is to test if the investigational medication ABT-089 is a safe and effective treatment for adults with Attention-Deficit/Hyperactivity Disorder (ADHD). Condition or disease Intervention/treatment Phase Attention-Deficit/Hyperactivity Disorder Drug: ABT-089 (...) Criteria: Have voluntarily signed an informed consent form. Meet diagnostic criteria for attention-deficit/hyperactivity disorder (ADHD) based on detailed evaluation and interview with subject. Subject is generally in good health based on medical history, physical examination, clinical lab tests and ECG. Female subjects of child-bearing potential must have a negative urine pregnancy test at screening and baseline and agree to comply with applicable contraceptive requirements. Male subjects must agree

2008 Clinical Trials

5200. A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD).

will receive 3 weeks of treatment with PF-03654746, either a low dose (1 mg), or flexible dose (0.50 mg titrated up to 2 mg), and 3 weeks of placebo. A washout period will separate the 2 treatment periods. Participants will be required to washout of prior ADHD medication before entering the study. Participants will be required to come to the site for 10 visits over approximately a 10-week period. Condition or disease Intervention/treatment Phase Attention Deficit Hyperactivity Disorder Drug: PF-03654746 (...) for additonal information Responsible Party: Pfizer ClinicalTrials.gov Identifier: Other Study ID Numbers: A8801004 3-WK, CO MTD IN ADULTS W/ADHD ( Other Identifier: Alias Study Number ) First Posted: September 19, 2007 Results First Posted: February 19, 2016 Last Update Posted: February 19, 2016 Last Verified: January 2016 Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Pathologic Processes Attention Deficit and Disruptive

2007 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>